Who is sponsoring NCT02240459?

NCT02240459 is sponsored by University of Alberta.

What condition does NCT02240459 study?

NCT02240459 studies Overactive Bladder, Mild Cognitive Impairment.

What drugs are being tested in NCT02240459?

Interventions: fesoterodine 4mg, Oxybutynin, placebo, fesoterodine 8mg.

What is the status of NCT02240459?

NCT02240459 is currently COMPLETED.

Last reviewed 2020-02-18 · How we verify

A Double Blind, Randomized Four Way Cross Over Study to Compare the Effect of Fesoterodine 4mg and 8mg Once Daily and Oxybutynin 5mg Twice Daily After Steady State Dosing Versus Placebo on Cognitive Function in Subjects With Overactive Bladder, Over the Age of 75 Years With Mild Cognitive Impairment

NCT02240459 Phase 2 COMPLETED

The purpose of this study is to assess the effects of fesoterodine at 4mg and 8mg doses versus a placebo and oxybutynin 5mg bid versus placebo on cognitive abilities in older people with overactive bladder and mild cognitive impairment.

Details

Lead sponsor	University of Alberta
Phase	Phase 2
Status	COMPLETED
Enrolment	47
Start date	2016-08
Completion	2020-01-31

Conditions

Overactive Bladder
Mild Cognitive Impairment

Interventions

fesoterodine 4mg
Oxybutynin
placebo
fesoterodine 8mg

Primary outcomes

continuity of attention — 1 and 4h post dose
Continuity of Attention: Accuracy of responding in Choice Reaction Time task Percent Target Detection in Digit Vigilance task False Alarms in Digit Vigilance task

Countries

Canada